PortalPublikationenSimultaneous Onset of Haematological Malignancy and COVID: A...

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Standard

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. / Cattaneo, Chiara; Salmanton-García, Jon; Marchesi, Francesco; El-Ashwah, Shaimaa; Itri, Federico; Weinbergerová, Barbora; Gomes Da Silva, Maria; Dargenio, Michelina; Dávila-Valls, Julio; Martín-Pérez, Sonia; Farina, Francesca; Van Doesum, Jaap; Valković, Toni; Besson, Caroline; Poulsen, Christian Bjørn; López-García, Alberto; Žák, Pavel; Schönlein, Martin; Piukovics, Klára; Jaksic, Ozren; Cabirta, Alba; Ali, Natasha; Sili, Uluhan; Fracchiolla, Nicola; Dragonetti, Giulia; Adžić-Vukičević, Tatjana; Marchetti, Monia; Machado, Marina; Glenthøj, Andreas; Finizio, Olimpia; Demirkan, Fatih; Blennow, Ola; Tisi, Maria Chiara; Omrani, Ali S; Navrátil, Milan; Ráčil, Zdeněk; Novák, Jan; Magliano, Gabriele; Jiménez, Moraima; Garcia-Vidal, Carolina; Erben, Nurettin; Del Principe, Maria Ilaria; Buquicchio, Caterina; Bergantim, Rui; Batinić, Josip; Al-Khabori, Murtadha; Verga, Luisa; Szotkowski, Tomáš; Samarkos, Michail; Ormazabal-Vélez, Irati; Meers, Stef; Maertens, Johan; Pinczés, László Imre; Hoenigl, Martin; Drgoňa, Ľuboš; Cuccaro, Annarosa; Bilgin, Yavuz M; Aujayeb, Avinash; Rahimli, Laman; Gräfe, Stefanie; Sciumè, Mariarita; Mladenović, Miloš; Çolak, Gökçe Melis; Sacchi, Maria Vittoria; Nordlander, Anna; Berg Venemyr, Caroline; Hanáková, Michaela; García-Poutón, Nicole; Emarah, Ziad; Zambrotta, Giovanni Paolo Maria; Nunes Rodrigues, Raquel; Cordoba, Raul; Méndez, Gustavo-Adolfo; Biernat, Monika M; Cornely, Oliver A; Pagano, Livio.

in: CANCERS, Jahrgang 14, Nr. 22, 5530, 10.11.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cattaneo, C, Salmanton-García, J, Marchesi, F, El-Ashwah, S, Itri, F, Weinbergerová, B, Gomes Da Silva, M, Dargenio, M, Dávila-Valls, J, Martín-Pérez, S, Farina, F, Van Doesum, J, Valković, T, Besson, C, Poulsen, CB, López-García, A, Žák, P, Schönlein, M, Piukovics, K, Jaksic, O, Cabirta, A, Ali, N, Sili, U, Fracchiolla, N, Dragonetti, G, Adžić-Vukičević, T, Marchetti, M, Machado, M, Glenthøj, A, Finizio, O, Demirkan, F, Blennow, O, Tisi, MC, Omrani, AS, Navrátil, M, Ráčil, Z, Novák, J, Magliano, G, Jiménez, M, Garcia-Vidal, C, Erben, N, Del Principe, MI, Buquicchio, C, Bergantim, R, Batinić, J, Al-Khabori, M, Verga, L, Szotkowski, T, Samarkos, M, Ormazabal-Vélez, I, Meers, S, Maertens, J, Pinczés, LI, Hoenigl, M, Drgoňa, Ľ, Cuccaro, A, Bilgin, YM, Aujayeb, A, Rahimli, L, Gräfe, S, Sciumè, M, Mladenović, M, Çolak, GM, Sacchi, MV, Nordlander, A, Berg Venemyr, C, Hanáková, M, García-Poutón, N, Emarah, Z, Zambrotta, GPM, Nunes Rodrigues, R, Cordoba, R, Méndez, G-A, Biernat, MM, Cornely, OA & Pagano, L 2022, 'Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey', CANCERS, Jg. 14, Nr. 22, 5530. https://doi.org/10.3390/cancers14225530

APA

Cattaneo, C., Salmanton-García, J., Marchesi, F., El-Ashwah, S., Itri, F., Weinbergerová, B., Gomes Da Silva, M., Dargenio, M., Dávila-Valls, J., Martín-Pérez, S., Farina, F., Van Doesum, J., Valković, T., Besson, C., Poulsen, C. B., López-García, A., Žák, P., Schönlein, M., Piukovics, K., ... Pagano, L. (2022). Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. CANCERS, 14(22), [5530]. https://doi.org/10.3390/cancers14225530

Vancouver

Cattaneo C, Salmanton-García J, Marchesi F, El-Ashwah S, Itri F, Weinbergerová B et al. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey. CANCERS. 2022 Nov 10;14(22). 5530. https://doi.org/10.3390/cancers14225530

Bibtex

@article{4ee3f4771a764b5b9e34ce785273d87a,
title = "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey",
abstract = "BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines.METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022.RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective.CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.",
author = "Chiara Cattaneo and Jon Salmanton-Garc{\'i}a and Francesco Marchesi and Shaimaa El-Ashwah and Federico Itri and Barbora Weinbergerov{\'a} and {Gomes Da Silva}, Maria and Michelina Dargenio and Julio D{\'a}vila-Valls and Sonia Mart{\'i}n-P{\'e}rez and Francesca Farina and {Van Doesum}, Jaap and Toni Valkovi{\'c} and Caroline Besson and Poulsen, {Christian Bj{\o}rn} and Alberto L{\'o}pez-Garc{\'i}a and Pavel {\v Z}{\'a}k and Martin Sch{\"o}nlein and Kl{\'a}ra Piukovics and Ozren Jaksic and Alba Cabirta and Natasha Ali and Uluhan Sili and Nicola Fracchiolla and Giulia Dragonetti and Tatjana Ad{\v z}i{\'c}-Vuki{\v c}evi{\'c} and Monia Marchetti and Marina Machado and Andreas Glenth{\o}j and Olimpia Finizio and Fatih Demirkan and Ola Blennow and Tisi, {Maria Chiara} and Omrani, {Ali S} and Milan Navr{\'a}til and Zden{\v e}k R{\'a}{\v c}il and Jan Nov{\'a}k and Gabriele Magliano and Moraima Jim{\'e}nez and Carolina Garcia-Vidal and Nurettin Erben and {Del Principe}, {Maria Ilaria} and Caterina Buquicchio and Rui Bergantim and Josip Batini{\'c} and Murtadha Al-Khabori and Luisa Verga and Tom{\'a}{\v s} Szotkowski and Michail Samarkos and Irati Ormazabal-V{\'e}lez and Stef Meers and Johan Maertens and Pincz{\'e}s, {L{\'a}szl{\'o} Imre} and Martin Hoenigl and {\v L}ubo{\v s} Drgo{\v n}a and Annarosa Cuccaro and Bilgin, {Yavuz M} and Avinash Aujayeb and Laman Rahimli and Stefanie Gr{\"a}fe and Mariarita Scium{\`e} and Milo{\v s} Mladenovi{\'c} and {\c C}olak, {G{\"o}k{\c c}e Melis} and Sacchi, {Maria Vittoria} and Anna Nordlander and {Berg Venemyr}, Caroline and Michaela Han{\'a}kov{\'a} and Nicole Garc{\'i}a-Pout{\'o}n and Ziad Emarah and Zambrotta, {Giovanni Paolo Maria} and {Nunes Rodrigues}, Raquel and Raul Cordoba and Gustavo-Adolfo M{\'e}ndez and Biernat, {Monika M} and Cornely, {Oliver A} and Livio Pagano",
year = "2022",
month = nov,
day = "10",
doi = "10.3390/cancers14225530",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "22",

}

RIS

TY - JOUR

T1 - Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

AU - Cattaneo, Chiara

AU - Salmanton-García, Jon

AU - Marchesi, Francesco

AU - El-Ashwah, Shaimaa

AU - Itri, Federico

AU - Weinbergerová, Barbora

AU - Gomes Da Silva, Maria

AU - Dargenio, Michelina

AU - Dávila-Valls, Julio

AU - Martín-Pérez, Sonia

AU - Farina, Francesca

AU - Van Doesum, Jaap

AU - Valković, Toni

AU - Besson, Caroline

AU - Poulsen, Christian Bjørn

AU - López-García, Alberto

AU - Žák, Pavel

AU - Schönlein, Martin

AU - Piukovics, Klára

AU - Jaksic, Ozren

AU - Cabirta, Alba

AU - Ali, Natasha

AU - Sili, Uluhan

AU - Fracchiolla, Nicola

AU - Dragonetti, Giulia

AU - Adžić-Vukičević, Tatjana

AU - Marchetti, Monia

AU - Machado, Marina

AU - Glenthøj, Andreas

AU - Finizio, Olimpia

AU - Demirkan, Fatih

AU - Blennow, Ola

AU - Tisi, Maria Chiara

AU - Omrani, Ali S

AU - Navrátil, Milan

AU - Ráčil, Zdeněk

AU - Novák, Jan

AU - Magliano, Gabriele

AU - Jiménez, Moraima

AU - Garcia-Vidal, Carolina

AU - Erben, Nurettin

AU - Del Principe, Maria Ilaria

AU - Buquicchio, Caterina

AU - Bergantim, Rui

AU - Batinić, Josip

AU - Al-Khabori, Murtadha

AU - Verga, Luisa

AU - Szotkowski, Tomáš

AU - Samarkos, Michail

AU - Ormazabal-Vélez, Irati

AU - Meers, Stef

AU - Maertens, Johan

AU - Pinczés, László Imre

AU - Hoenigl, Martin

AU - Drgoňa, Ľuboš

AU - Cuccaro, Annarosa

AU - Bilgin, Yavuz M

AU - Aujayeb, Avinash

AU - Rahimli, Laman

AU - Gräfe, Stefanie

AU - Sciumè, Mariarita

AU - Mladenović, Miloš

AU - Çolak, Gökçe Melis

AU - Sacchi, Maria Vittoria

AU - Nordlander, Anna

AU - Berg Venemyr, Caroline

AU - Hanáková, Michaela

AU - García-Poutón, Nicole

AU - Emarah, Ziad

AU - Zambrotta, Giovanni Paolo Maria

AU - Nunes Rodrigues, Raquel

AU - Cordoba, Raul

AU - Méndez, Gustavo-Adolfo

AU - Biernat, Monika M

AU - Cornely, Oliver A

AU - Pagano, Livio

PY - 2022/11/10

Y1 - 2022/11/10

N2 - BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines.METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022.RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective.CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

AB - BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines.METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022.RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective.CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

U2 - 10.3390/cancers14225530

DO - 10.3390/cancers14225530

M3 - SCORING: Journal article

C2 - 36428621

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 22

M1 - 5530

ER -